

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph starting at page 40, line 20 with the following amended paragraph:

It can be also confirmed that the compound of the present specification, when it is topically administered, is converted to a degraded compound in the blood, etc. in human or animal for example, by its half life in the serum or in ~~lever-liver~~ S9 in vitro. The test method to determine the half life of the compound of the present invention in vitro is known.

Please replace the paragraph starting on page 41, line 4 with the following amended paragraph:

The compound of the present invention is added to ~~lever-liver~~ S9 solution, and the mixture is incubated at $37 \pm 0.5^{\circ}\text{C}$ for 5 minutes to 2 hours. By quantitatively analyzing at the definite interval the amount of the compound of the present invention remaining in the liver S9 solution with HPLC (high performance liquid chromatography), etc., the constant of quenching velocity is calculated and the half life is calculated. The ~~lever-liver~~ S9 means the supernatant prepared by the lever of mammalian being homogenated in an aqueous solution, such as physiological saline, sucrose solution, KCI solution, etc., the homogenate being centrifuged at 9000xg and its supernatant fraction being collected. The aqueous solution is usually used 2 to 4 times as much as the amount of lever. The ~~lever-liver~~ of human, dog, rabbit, guinea pig, rat, mouse, etc. are used. The ~~lever-liver~~ S9 diluted with buffer, etc., if necessary can be used.